Entera Bio Ltd. (ENTX)’s Financial Results Comparing With Melinta Therapeutics Inc. (NASDAQ:MLNT)

This is therefore a comparing of the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation in Entera Bio Ltd. (NASDAQ:ENTX) and Melinta Therapeutics Inc. (NASDAQ:MLNT). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio Ltd. 4 54.25 N/A -0.90 0.00
Melinta Therapeutics Inc. 4 0.41 N/A -15.68 0.00

Table 1 highlights Entera Bio Ltd. and Melinta Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides Entera Bio Ltd. and Melinta Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Entera Bio Ltd. 0.00% 0% -75.7%
Melinta Therapeutics Inc. 0.00% -71.6% -32.3%


4.6 and 4.6 are the respective Current Ratio and a Quick Ratio of Entera Bio Ltd. Its rival Melinta Therapeutics Inc.’s Current and Quick Ratios are 1.4 and 1.1 respectively. Entera Bio Ltd. has a better chance of clearing its pay short and long-term debts than Melinta Therapeutics Inc.

Insider & Institutional Ownership

Institutional investors owned 14.8% of Entera Bio Ltd. shares and 24.3% of Melinta Therapeutics Inc. shares. Insiders owned 46.55% of Entera Bio Ltd. shares. Competitively, 0.3% are Melinta Therapeutics Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Entera Bio Ltd. -8.91% -12.8% -22.33% 1.55% 0% 7.21%
Melinta Therapeutics Inc. -1.73% -43.69% -5.92% -4.34% -84.58% 0.16%

For the past year Entera Bio Ltd. has stronger performance than Melinta Therapeutics Inc.


On 5 of the 7 factors Entera Bio Ltd. beats Melinta Therapeutics Inc.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.